Group 1 - The company Zhongyuan Qihe announced its participation in the 2025 Tianjin-listed companies investor online reception day and semi-annual performance briefing [2] - The event is scheduled for September 11, 2025 [2]

证券代码：600645 证券简称：中源协和 公告编号：2025-036 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景 路演 APP，参与本次互动交流。活动时间为 2025 年 9 月 11 日（周四）15:00-17:00。 出席本次活动的有公司副董事长、总经理 WANG HONGQI（王洪琦）先生， 独立董事侯欣一先生和罗明生先生，副总经理、财务总监兼董事会秘书陈轶青先 生（如有特殊情况，出席人员会有调整）。届时公司将在线就公司 2025 年半年度 业绩、公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行沟通 与交流，欢迎广大投资者踊跃参与！ 特此公告。 中源协和细胞基因工程股份有限公司 二○二五年九月五日 1 中源协和细胞基因工程股份有限公司 关于参加 2025 年天津辖区上市公司投资者网上集体 接待日暨半年报业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流 ...

Market Overview - The recombinant protein sector experienced a decline of 1.01%, ranking among the top losers in concept sectors as of the market close on August 28 [1] - Notable declines within the sector included companies such as Aladdin, Bory Pharmaceutical, and Zhongyuan Union, while Chengdu XianDao, Dezhan Health, and Betta Pharmaceuticals saw increases of 7.44%, 2.38%, and 2.02% respectively [1] Concept Sector Performance - The top-performing concept sectors included Copper Cable High-Speed Connection (+5.61%), Co-Packaged Optics (+5.13%), and F5G Concept (+5.12%), while the recombinant protein sector was among the laggards with a decline of 1.01% [2] Capital Flow Analysis - The recombinant protein sector faced a net outflow of 1.348 billion yuan, with 41 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2] - Bory Pharmaceutical led the outflows with a net outflow of 548 million yuan, followed by Zhifei Biological, Hualan Biological, and Zhongyuan Union with net outflows of 149 million yuan, 88.91 million yuan, and 77.72 million yuan respectively [2] Individual Stock Performance - Bory Pharmaceutical reported a decline of 6.63% with a turnover rate of 5.33% and a net outflow of 547.71 million yuan [3] - Chengdu XianDao was the standout performer in the sector, increasing by 7.44% despite a net outflow of 203.74 million yuan [3] - Other notable stocks with significant net inflows included Dezhan Health (+2.38%) with a net inflow of 46.14 million yuan, Haoyuan Pharmaceutical (+1.82%) with a net inflow of 18.75 million yuan, and Maimai Biological (+1.82%) with a net inflow of 18.75 million yuan [4]

格隆汇8月27日丨中源协和(600645.SH)发布2025年半年度报告，报告期实现营业收入7.16亿元，同比下 降10.71%；归属上市公司股东的净利润5777.05万元，同比下降32.18%；扣除非经常性损益后的归属于 上市公司股东的净利润5389.17万元，同比下降35.82%；基本每股收益0.13元。 ...

中源协和细胞基因工程股份有限公司（以下简称"公司"）十一届二十一 次董事会会议于 2025 年 8 月 27 日以通讯表决方式召开。会议通知和会议资料 已于 2025 年 8 月 16 日以电子邮件形式向全体董事发出。应出席会议的董事 9 名，实际出席会议的董事 9 名。会议符合《公司法》和《公司章程》的规定， 表决有效。经出席会议的董事认真审议，通过了以下决议： 1、以 9 票赞成、0 票反对、0 票弃权，审议通过了《公司 2025 年半年度报 告》全文及摘要； 证券代码：600645 证券简称：中源协和 公告编号：2025-033 中源协和细胞基因工程股份有限公司 十一届二十一次董事会会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本议案经公司第十一届董事会审计委员会 2025 年第五次会议审议通过。 《公司 2025 年半年度报告》全文及摘要详见上海证券交易所网站 www.sse.com.cn。 2、以 9 票赞成、0 票反对、0 票弃权，审议通过了《公司 2025 年半年度募 集资金存放与实际使用情况的专 ...

[Definitions](index=4&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8A%E4%B9%89) [Definitions of Common Terms](index=4&type=section&id=%E5%B8%B8%E7%94%A8%E8%AF%8D%E8%AF%AD%E9%87%8A%E4%B9%89) This chapter defines key terms, regulatory bodies, company entities, biotechnology terms, and reporting periods for clear understanding of the report content - The report defines key entities and professional terms such as **China Securities Regulatory Commission (CSRC)**, **the Company**, **Jiadao Success**, **Deyuan Health**, **OriGene Technologies, Inc.**, **In Vitro Diagnostics (IVD)**, **Mesenchymal Stem Cells (MSC)**, **induced Pluripotent Stem Cells (iPSC)**, **National Medical Products Administration (NMPA)**, **Center for Drug Evaluation (CDE)**, and **Food and Drug Administration (FDA)**[15](index=15&type=chunk) [Company Profile and Key Financial Indicators](index=4&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section provides an overview of the company's basic information and key financial performance indicators [Company Information](index=4&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E4%BF%A1%E6%81%AF) This section presents the company's fundamental registration details, including its Chinese name, abbreviation, foreign name, and legal representative Company Basic Information | Metric | Content | | :--- | :--- | | Chinese Name | 中源协和细胞基因工程股份有限公司 | | Chinese Abbreviation | 中源协和 | | Foreign Name | VCANBIO CELL & GENE ENGINEERING CORP., LTD | | Legal Representative | WANG HONGQI（王洪琦） | [Contacts and Contact Information](index=4&type=section&id=%E4%BA%8C%E3%80%81%E8%81%94%E7%B3%BB%E4%BA%BA%E5%92%8C%E8%81%94%E7%B3%BB%E6%96%B9%E5%BC%8F) This section provides contact information for the company's Board Secretary and Securities Affairs Representative, including names, addresses, phone numbers, faxes, and email addresses Contact Information | Position | Name | Contact Address | Phone | Fax | Email | | :--- | :--- | :--- | :--- | :--- | :--- | | Board Secretary | 陈轶青 | 天津市滨海高新区华苑产业区梅苑路12号 | 022-58617160 | 022-58617161 | zhongyuanxiehe@vcanbio.com | | Securities Affairs Representative | 张奋 | 天津市滨海高新区华苑产业区梅苑路12号 | 022-58617160 | 022-58617161 | zhongyuanxiehe@vcanbio.com | [Brief Introduction to Changes in Basic Information](index=5&type=section&id=%E4%B8%89%E3%80%81%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5%E5%8F%98%E6%9B%B4%E7%AE%80%E4%BB%8B) This section outlines the company's current registered and office addresses, noting that historical changes are available in company announcements - The company's registered address is Floor 2, Building A, No. 12 Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin, and its office address is No. 12 Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin[17](index=17&type=chunk) [Brief Introduction to Changes in Information Disclosure and Document Custody Locations](index=5&type=section&id=%E5%9B%9B%E3%80%81%E4%BF%A1%E6%81%AF%E6%8A%AB%E9%9C%B2%E5%8F%8A%E5%A4%87%E7%BD%AE%E5%9C%B0%E7%82%B9%E5%8F%98%E6%9B%B4%E6%83%85%E5%86%B5%E7%AE%80%E4%BB%8B) This section specifies the company's designated newspapers for information disclosure, the website for report publication, and the location for report availability - The company designates "China Securities Journal", "Shanghai Securities News", and "Securities Times" as its information disclosure newspapers, with the semi-annual report published on www.sse.com.cn and available at No. 12 Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin[18](index=18&type=chunk) [Overview of Company Shares](index=5&type=section&id=%E4%BA%94%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E7%A5%A8%E7%AE%80%E5%86%B5) This section provides a brief overview of the company's A-share stock, including its listing exchange, abbreviation, and code Company Stock Overview | Share Type | Listing Exchange | Stock Abbreviation | Stock Code | | :--- | :--- | :--- | :--- | | A股 | 上海证券交易所 | 中源协和 | 600645 | [Company's Key Accounting Data and Financial Indicators](index=5&type=section&id=%E4%B8%83%E3%80%81%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section presents the company's key accounting data and financial indicators for the current and prior periods, explaining the reasons for profit decline Key Accounting Data (Unit: yuan) | Item | Current Period (Jan-Jun) | Prior Period | Change from Prior Period (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 716,369,723.52 | 802,285,328.09 | -10.71 | | Total Profit | 74,744,079.80 | 114,140,321.07 | -34.52 | | Net Profit Attributable to Shareholders | 57,770,452.54 | 85,185,087.67 | -32.18 | | Net Cash Flow from Operating Activities | 123,036,717.91 | 98,635,675.90 | 24.74 | Key Financial Indicators (Unit: yuan/share) | Item | Current Period (Jan-Jun) | Prior Period | Change from Prior Period (%) | | :--- | :--- | :--- | :--- | | Basic EPS | 0.13 | 0.18 | -27.78 | | Diluted EPS | 0.13 | 0.18 | -27.78 | | Basic EPS after Non-recurring Gain/Loss | 0.12 | 0.18 | -33.33 | | Weighted Avg. ROE (%) | 1.59 | 2.32 | 减少0.73个百分点 | - The company's total profit, net profit attributable to shareholders, and net profit attributable to shareholders after non-recurring gain/loss decreased from the prior period, primarily due to a decline in reagent segment revenue and a year-on-year decrease in net profit[23](index=23&type=chunk) [Non-recurring Gain/Loss Items and Amounts](index=6&type=section&id=%E4%B9%9D%E3%80%81%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) This section details the non-recurring gain/loss items and their amounts for the reporting period, totaling **3.88 million yuan** Non-recurring Gain/Loss Items and Amounts (Unit: yuan) | Non-recurring Gain/Loss Item | Amount | | :--- | :--- | | Gain/Loss on Disposal of Non-current Assets | -332,722.36 | | Government Grants Recognized in Current P&L | 1,163,733.71 | | Fair Value Change G/L & Disposal G/L from Fin. Assets/Liabilities | 5,000,290.13 | | Reversal of Impairment for Receivables Individually Assessed | 351,418.58 | | Other Non-operating Income & Expenses | -223,827.70 | | Other Non-recurring G/L Items | -1,543,812.26 | | Less: Income Tax Impact | 370,288.98 | | Minority Interest Impact (After Tax) | 166,023.23 | | **Total** | **

证券之星消息，8月20日医疗器械板块较上一交易日上涨0.06%，济民健康领涨。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。医疗器械板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603222 | 济民健康 | 11.86 | 10.02% | 164.39万 | | 18.28亿 | | 300642 | 透景生命 | 24.81 | 7.45% | 35.17万 | | 8.65 Z | | 688581 | 安杰思 | 87.93 | 6.07% | 2.57万 | | 2.20亿 | | 301093 | 华兰股份 | 34.04 | 4.58% | 13.19万 | | 4.45亿 | | 600645 | 中源协和 | 29.66 | 3.27% | 23.37万 | | ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗器械板块主力资金净流出6.22亿元，游资资金净流入8454.45万元，散户资 金净流入5.38亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300049 | 福瑞股份 | 1.46 Z | 11.88% | -1.05 Z | -8.52% | -4138.97万 | -3.36% | | 300003 | 乐普医疗 | 1.21 Z | 7.97% | -5108.00万 | -3.37% | -6962.47万 | -4.59% | | 600645 | 中源协和 | 9348.49万 | 9.75% | -3949.64万 | -4.12% | -5398.85万 | -5.63% | | 688271 | 联影医疗 | ...

Group 1 - The core announcement is that the company's wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., has received a notice of acceptance for the clinical trial application of VUM02 injection from the National Medical Products Administration (NMPA) [1] - VUM02 injection is a cryopreserved cell preparation developed by the company, derived from umbilical cord mesenchymal stem cells (UC-MSC), aimed at treating post-pneumonia pulmonary fibrosis [2] - As of June 2025, the total R&D investment for the related project has reached RMB 22.33 million [2]

Core Viewpoint - Zhongyuan Union announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received the acceptance notice for the clinical trial application of VUM02 injection from the National Medical Products Administration (NMPA) on August 1, 2025 [1] Group 1 - The clinical trial application for VUM02 injection has been officially accepted by the NMPA [1]